AstraZeneca snaps up Icosavax for $1.1 billion

Dealmaking may be a bit lacklustre at the moment but if there is one sector that is seeing a lot of activity right now it's the biotechnology industry.

The latest deal to be announced is AstraZeneca's $1.1 acquisition of Icosavax, a US-listed developer of vaccines for respitory diseases.

The FTSE 100-listed pharmaceutical giant is initial paying around $800 million for Icosavax but that could rise to $1.1 billion if certain regulatory hurdles and sales targets are met. Below is a link to the details of the deal:..


Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Tuesday, 12 December 2023, 8:39 am

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation